Jonathan Rick is a Dermatology physician affiliated with University of California, Davis. OpenAlex indexes 116 publications with 2,130 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3105 Cedar Ravine Rd Ste 201
Placerville, CA 956676561
Telephone
530-626-1602Provider last certified this registry record 23 Jul 2024.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202512 payments
- BeiGene, Ltd.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
36.6%Azole Antifungal21.5%Ketoconazole100%Part D≥140 patientsTetracycline-class Drug11.6%Doxycycline Hyclate71%Doxycycline Monohydrate29%Part D≥57 patients+ 2 more classes in this area
Dermatology
31.1%Corticosteroid24.2%Triamcinolone Acetonide77%Triamcinolone acetonide23%Part D + Part B≥169 patientsInterleukin-4 Receptor alpha Antagonist4.2%Dupixent Pen100%Part D≥11 patients+ 2 more classes in this area
Sensory organs
12%Corticosteroid12%Clobetasol Propionate64%Hydrocortisone36%Part D≥67 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database
Journal of the American Academy of Dermatology
2025 - Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects
Journal of Clinical Investigation
2023 - Low Rates of Psychosocial Screening and Lifestyle Counseling in Hidradenitis Suppurativa Patients in the USA
Skin Appendage Disorders
2023 - A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative
British Journal of Dermatology
2023 - COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study
Skin Appendage Disorders
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ezra Amsterdam, MD
University of California, Davis
Michael Rogawski, MD
University of California, Davis
Christopher Bowlus, MD
University of California, Davis
Emanual Maverakis, MD
University of California, Davis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”